Zacks Investment Research upgraded shares of Urogen Pharma (NASDAQ:URGN) from a sell rating to a hold rating in a research report sent to investors on Wednesday, October 18th.
According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “
Other analysts also recently issued reports about the company. Jefferies Group LLC upped their price objective on Urogen Pharma from $27.00 to $37.00 and gave the company a buy rating in a research report on Monday, October 9th. Oppenheimer Holdings, Inc. set a $32.00 target price on Urogen Pharma and gave the stock a buy rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Urogen Pharma presently has an average rating of Buy and an average target price of $28.50.
Urogen Pharma (NASDAQ URGN) remained flat at $$36.82 on Wednesday. 378,663 shares of the company’s stock traded hands, compared to its average volume of 42,924. Urogen Pharma has a fifty-two week low of $13.01 and a fifty-two week high of $38.38.
ILLEGAL ACTIVITY WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/urogen-pharma-urgn-lifted-to-hold-at-zacks-investment-research/1722817.html.
A number of large investors have recently made changes to their positions in URGN. State of Tennessee Treasury Department acquired a new stake in shares of Urogen Pharma in the third quarter valued at about $158,000. Alps Advisors Inc. acquired a new stake in shares of Urogen Pharma in the second quarter valued at about $195,000. Shikiar Asset Management Inc. acquired a new stake in shares of Urogen Pharma in the third quarter valued at about $665,000. LLBH Private Wealth Management LLC acquired a new stake in shares of Urogen Pharma in the second quarter valued at about $695,000. Finally, Spark Investment Management LLC acquired a new stake in shares of Urogen Pharma in the second quarter valued at about $856,000. Institutional investors own 40.93% of the company’s stock.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with our FREE daily email newsletter.